Major Depressive Disorder News and Research RSS Feed - Major Depressive Disorder News and Research

Current psychotherapy treatments less than optimal for war veterans suffering from PTSD

Current psychotherapy treatments less than optimal for war veterans suffering from PTSD

Our nation's veterans continue to suffer emotional and psychological effects of war—some for decades. And while there has been greater attention directed recently toward post-traumatic stress disorder (PTSD), and more veterans are seeking help, current psychotherapy treatments are less than optimal, according to a new narrative review published in the August 4, 2015 issue of JAMA. [More]
Study reveals potential new therapeutic target for depression treatment

Study reveals potential new therapeutic target for depression treatment

Increasing the levels of a signaling molecule found in the brain can positively alter response to stress, revealing a potential new therapeutic target for treatment of depression, UT Southwestern Medical Center researchers said. [More]
New research shows that pupil response can predict child's risk of depression

New research shows that pupil response can predict child's risk of depression

How much a child's pupil dilates in response to seeing an emotional image can predict his or her risk of depression over the next two years, according to new research from Binghamton University. [More]
Virtual human helps veterans with PTSD, people with mental illness build job interview skills

Virtual human helps veterans with PTSD, people with mental illness build job interview skills

Finding a job is difficult for veterans with posttraumatic stress disorder (PTSD) and individuals with severe mental illness, who have high unemployment rates even though many want to work. [More]
Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem's HK532-IGF-1 neural stem cells therapy for Alzheimer's disease presented at ISSCR Annual Meeting

Neuralstem, Inc., a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, announced that the poster "Human Neural Stem Cells Expressing IGF-1: A Novel Cellular Therapy for Alzheimer's Disease" was presented yesterday at the International Society for Stem Cell Research (ISSCR) Annual Meeting in Stockholm, Sweden. [More]
New depression treatment from Magstim to be exhibited at Royal College of Psychiatry International Congress 2015

New depression treatment from Magstim to be exhibited at Royal College of Psychiatry International Congress 2015

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, will be showing its Magstim Rapid2 Therapy System at the Royal College of Psychiatry International Congress 2015 in Birmingham, UK, 29th June-2nd July. [More]
Recurrent major depression may increase osteoporosis risk in men

Recurrent major depression may increase osteoporosis risk in men

A recent study from the University of Eastern Finland in collaboration with Deakin University, Australia, shows that recurrent major depressive disorder (MDD) in men is associated with lower bone density. The use of antidepressants was also associated with lower bone mineral density (BMD), but this association was dependent on the person's weight and site of bone measurement. [More]
People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health

People across the world are living longer but spending more time in ill health as rates of nonfatal diseases and injuries - including diabetes and hearing loss - decline more slowly than death rates, according to a new analysis of 301 diseases and injuries in 188 countries. [More]
Emotion regulation distinguishes unipolar and bipolar depression

Emotion regulation distinguishes unipolar and bipolar depression

Patients with bipolar disorder regulate their emotions differently from those with major depressive disorder in both depressed and remitted states, a study shows. [More]
Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

Magstim Rapid2 Therapy System receives FDA clearance for treatment of drug resistant MDD

The Magstim Company Ltd, an innovative and award winning Wales-based medical device manufacturer, has received FDA 510(k) clearance to market its Magstim Rapid2 Therapy System for the treatment of drug resistant Major Depressive Disorder (MDD) in the United States. The clearance enables Magstim to significantly increase access to cutting-edge Repetitive Transcranial Magnetic Stimulation (rTMS) technology for patients and clinicians. [More]
Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015. [More]
MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI completes patient recruitment for STRADA Phase 2 trial for treatment of major depressive disorder

MSI Methylation Sciences, Inc., a pharmaceutical company developing a once-daily oral, small molecule therapy for adjunctive treatment of major depressive disorder (MDD), announced the completion of patient recruitment for its HORIZON Phase 2 Study. [More]
Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

Johns Hopkins researchers develop new strategies to treat depression in children, adolescents

A multidisciplinary team of Johns Hopkins researchers has developed two new strategies to treat depression in young people using the selective serotonin reuptake inhibitor (SSRI) class of medications. These strategies, published May 5 in the journal Translational Psychiatry, incorporate a new understanding of how to mitigate the risk of suicide while on SSRI treatment. [More]
Clinical features identified to distinguish bipolar I disorder from MDD

Clinical features identified to distinguish bipolar I disorder from MDD

Researchers have identified seven clinical features that could help distinguish patients with bipolar disorder from those with major depressive disorder. [More]
Neuronetics completes Series F Financing Round

Neuronetics completes Series F Financing Round

Neuronetics, Inc., the established market leader in transcranial magnetic stimulation (TMS) technology, announced today the completion of its Series F Financing Round, which included investment from GE Ventures, as well as its original investor base totaling $34.3 million. [More]
Tal Medical raises $14 million funding round from new and existing investors

Tal Medical raises $14 million funding round from new and existing investors

Tal Medical, a clinical-stage medical device company developing a new treatment for depression and other psychiatric disorders, today announced a $14 million funding round from existing investor PureTech, a new institutional investor, and several prominent individual investors. [More]
Roseroot extract may be beneficial for treating major depressive disorder

Roseroot extract may be beneficial for treating major depressive disorder

Rhodiola rosea (R. rosea), or roseroot, may be a beneficial treatment option for major depressive disorder (MDD), according to results of a study in the journal Phytomedicine led by Jun J. Mao, MD, MSCE, associate professor of Family Medicine, Community Health and Epidemiology and colleagues at the Perelman School of Medicine of University of Pennsylvania. [More]
Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Deuterium-containing sigma-1 agonist demonstrates anti-seizure, anti-inflammatory effects in TBI model

Research results published in the Journal of Neurotrauma and conducted by the Walter Reed Army Institute of Research (WRAIR) as part of a collaboration with Concert Pharmaceuticals, Inc. showed that a novel deuterium-containing sigma-1 agonist invented at Concert, called C-10068, demonstrated anti-seizure and anti-inflammatory effects in a preclinical model of traumatic brain injury (TBI). [More]
Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem reports top line data from NSI-566 Phase II trial for treatment of ALS

Neuralstem, Inc. announced top line data from the Phase II trial of NSI-566 spinal cord-derived neural stem cells under development for the treatment of amyotrophic lateral sclerosis (ALS). The study met primary safety endpoints. The maximum tolerated dose of 16 million transplanted cells and the surgery was well tolerated. [More]
Study finding suggests importance of individually-tailored treatment for depression

Study finding suggests importance of individually-tailored treatment for depression

The most commonly used treatment for the over 14 million Americans who suffer from Major Depressive Disorder is anti-depressant medication. While such medications bring relief to many, current research suggests that one size may not fit all when it comes to treating depression. [More]
Advertisement
Advertisement